New research may have people with asthma breathing a little easier: Doctors found the airway disease doesn’t raise the risk of being hospitalized due to COVID-19.

The researchers also noted that people with asthma weren’t more likely than people without it to need a ventilator to help them breathe.

“A lot of people with asthma think they have a predisposition to severe COVID, and they worry a lot about going out. They should take precautions like using their masks, but they may not need to worry so much,” said study author Dr. Fernando Holguin. He’s director of the Asthma Clinical and Research Program at the University of Colorado Anschutz Medical Campus, in Aurora.

Holguin said the proportion of hospitalized COVID-19 patients with asthma was around 6%.

“For most places, that’s an asthma prevalence that is at or lower than the asthma prevalence in the general population. To compare, with influenza [flu], we typically see about a quarter of those in the hospital have asthma,” he said.

When the pandemic first began, the U.S. Centers for Disease Control and Prevention suggested that people with asthma had a higher risk of hospitalization and other severe outcomes. People with asthma do have a significantly higher risk of complications with flu, another viral infection.

In the new study, the researchers reviewed 15 studies on COVID-19 infections to see how many people hospitalized had asthma. They also looked at more than 400 patients treated for COVID-19 at the University of Colorado Hospital, to see whether the rates of ventilator use were different in people with asthma.

“The message from our study is not to be cavalier about COVID, but individuals with asthma won’t do worse than people without it,” Holguin said.

Other research also points to the same conclusion. A June study in the Journal of Allergy and Clinical Immunology of more than 1,500 people (220 with asthma) who had COVID-19 found that people with asthma weren’t more likely to be hospitalized. They also didn’t have a higher risk of death.

Holguin said the researchers have a theory as to why COVID-19 infections don’t seem to lead to worse outcomes in people with asthma.

“Allergic asthma is associated with lower numbers of ACE2 receptors. These are the receptors the virus uses to anchor itself to cells,” he said. That means people with allergic asthma may have less area for the virus to attach to. Holguin added that people who use inhaled corticosteroids (an asthma treatment) also have fewer ACE2 receptors.

The new findings were published Aug. 31 in the Annals of the American Thoracic Society.

Dr. Charles Fishman, a pulmonologist with the NewYork-Presbyterian Medical Group Westchester, in New York City, said, “This study’s findings are consistent with what we’ve seen clinically. The original concern was that since people with asthma are disproportionately hospitalized with flu, that they might also have bad outcomes with coronavirus. But that doesn’t seem to be the case with coronavirus.”

Fishman said it’s probably too soon to know why people with asthma are faring better than expected.

“There so much that’s still unknown. It’s important in drawing conclusions that we really rely on good science,” he added.

In the meantime, like Holguin, he advised, “People with asthma should exercise the exact same caution as people without asthma. They don’t need to be increasingly concerned, but should have a healthy respect for what this virus can do. Until a vaccine is available and the population is fully protected, continue to do those things that protect you from the virus [such as wearing a mask, washing your hands frequently and keeping safe distances from others].”

People with lupus aren’t at increased risk of hospitalization from COVID-19 due to steroidal medications they take to reduce immune system activity, a new study finds.

And a related study found that people with inflammatory forms of arthritis — such as rheumatoid arthritis — aren’t more likely to be hospitalized with COVID-19 than people without arthritis.

Both studies were led by researchers at NYU Grossman School of Medicine, in New York City.

The findings “should reassure most patients, especially those on immunosuppressant therapy, that they are at no greater risk of having to be admitted to hospital from COVID-19 than other lupus or arthritis patients,” Dr. Ruth Fernandez-Ruiz, co-author of the studies, said in an NYU Langone news release.

“People with lupus or inflammatory arthritis have the same risk factors for getting seriously ill from COVID-19 as people without these disorders,” said Fernandez-Ruiz, a postdoctoral fellow in rheumatology.

Lupus and conditions like rheumatoid arthritis, psoriatic arthritis and spondyloarthritis are autoimmune diseases in which the immune system mistakenly attacks a person’s own tissues. This causes inflammation in the joints, skin, kidneys and other parts of the body.

The researchers found that lupus patients taking immune-suppressing medications — such as mycophenolate mofetil (CellCept) and azathioprine (Imuran) — had no greater risk of hospitalization (15 out of 24) than lupus patients not using the medications (nine of 17).

In addition, the COVID-19 hospitalization rate for people with inflammatory arthritis (26%) was similar to that of New York City residents overall (25%).

Another finding was that patients taking biologic drugs for arthritis, such as adalimumab (Humira) and etanercept (Enbrel), or the antiviral hydroxychloroquine, had no greater or lower risk of COVID-19 hospitalization than those not taking the drugs.

But patients who took steroids called glucocorticoids, even in mild doses, had a 10 times higher risk of COVID-19 hospitalization than those who didn’t take steroids. Although the finding is statistically significant, the study’s small size may overestimate the actual risk, the researchers noted.

The studies were recently published online in the journal Arthritis and Rheumatology.